AK Medical Announces Significant Increase in Share Repurchase Programme to HK\$500 Million
AK Medical Holdings Limited (“AK Medical” or the “Company”, stock code: 1789) has made a major announcement regarding its share repurchase activities, which could have a significant impact on its share price and investor sentiment.
Key Points from the Announcement
- Share Repurchase Mandate: The Board of Directors has resolved to exercise the general mandate granted by shareholders at the 2025 AGM to repurchase up to 10% of the Company’s issued shares (equivalent to 112,269,577 shares).
- Massive Budget Increase: The Company has increased the budget for share repurchases from HK\$150 million to HK\$500 million, representing a more than threefold expansion of the original plan.
- Timeline: The repurchase programme is valid up to 17 June 2026, coinciding with the next annual general meeting.
- Execution: Purchases will be made on the open market of the Hong Kong Stock Exchange, subject to market conditions and at the Board’s discretion.
- Treasury Shares: All repurchased shares will be held as treasury shares rather than being cancelled, providing the Company with flexibility for future use.
- Progress So Far: As of 5 June 2026, AK Medical has already repurchased 14,462,000 shares for a total consideration of approximately HK\$87.65 million.
- Funding: The repurchase will be financed entirely by internal financial resources, and the Board believes it will not compromise the Company’s solid financial position.
- Compliance: The repurchase will strictly adhere to the Articles of Association, Hong Kong Listing Rules, Takeovers and Share Buy-backs Codes, Cayman Islands Companies Act, and other applicable regulations.
- Public Float: The Company has committed that the share repurchase will not reduce the public float below required minimum levels.
Shareholder and Investor Considerations
- Potential Price Sensitivity: The substantial increase in repurchase budget is a strong signal of confidence from the Board in the Group’s business outlook and may lead to upward pressure on the share price due to reduced free float and improved market sentiment.
- Market Conditions: The timing, quantity, and price of repurchases remain at the Board’s absolute discretion and depend on prevailing market conditions. There is no guarantee as to the specific execution details.
- Risk Advisory: Shareholders and investors are advised to exercise caution when dealing in the shares, as the repurchase programme’s actual scale and pace may fluctuate.
Board Statement
The Board stated that this move reflects their confidence in the business outlook and future prospects of the Group. The repurchase is aimed at creating value for shareholders while maintaining a strong financial position.
Board Composition
The announcement was signed by Chairman Li Zhijiang and lists all current Board members, including executive, non-executive, and independent non-executive directors.
Conclusion
This announcement of a substantial increase in the share repurchase programme is likely to be price-sensitive and could have a material impact on AK Medical’s share price and investor perception. Investors are encouraged to stay alert to further updates and monitor the Company’s activity closely.
Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors should make their own assessment and seek professional advice where appropriate. The actual scale and timing of share repurchases are subject to market conditions and the Board’s discretion, and there is no guarantee that the full amount will be utilized.
愛康醫療股份有限公司大幅增加股份回購計劃至5億港元
愛康醫療控股有限公司（「愛康醫療」或「公司」，股份代號：1789）最近公布了一項有可能對股價及投資者情緒產生重大影響的股份回購計劃重大調整。
公告重點
- 股份回購授權： 董事會已決定行使於2025年股東周年大會授出的普通授權，回購公司已發行股份的最多10%（相當於112,269,577股）。
- 大幅增加預算： 公司已將股份回購預算由原定的1.5億港元大幅增至5億港元，增幅超過三倍。
- 期限： 回購計劃有效期至2026年6月17日，即下一屆股東周年大會。
- 執行方式： 回購股份將於香港聯合交易所公開市場進行，具體時間及數量將視乎市場情況並由董事會酌情決定。
- 庫藏股： 全數回購股份將作庫藏股處理，而非註銷，為公司未來靈活運用提供空間。
- 最新進度： 截至2026年6月5日，公司已回購14,462,000股，總代價約8,765.2萬港元。
- 資金來源： 全部回購資金將以公司內部資金支付，董事會認為不會影響公司穩健的財務狀況。
- 合規性： 回購將嚴格遵守公司章程、香港上市規則、收購及股份回購守則、開曼群島公司法及所有相關法規。
- 公眾持股比例： 公司承諾回購不會令公眾持股量低於上市規定的最低標準。
股東及投資者需注意事項
- 潛在價格敏感： 大幅提升回購額，反映董事會對集團前景充滿信心，有機會帶動股價上升，市場情緒向好。
- 市場情況： 回購的時間、數量及價格完全由董事會酌情決定，需視乎市場情況，最終執行細節尚未有保證。
- 風險提示： 股東及潛在投資者在買賣公司股份時應審慎行事，因為實際回購規模及進度可能有變。
董事會聲明
董事會表示，這次重大舉措展現了對集團業務前景的信心，期望為股東創造價值，同時維持公司穩健的財務狀況。
董事會成員
公告由董事長李志強簽署，並列明所有執行、非執行及獨立非執行董事名單。
總結
這次大幅增加股份回購計劃的公告，屬於高度價格敏感資訊，或將對愛康醫療的股價及市場信心產生重大影響。建議投資者密切留意公司後續動態。
免責聲明： 以上內容僅供資訊參考，並不構成任何投資建議。投資者應自行作出判斷並諮詢專業意見。股份回購的實際規模及進度由市場情況及董事會酌情決定，最終未必會動用全部預算金額。
